Alvimopan
Alvimopan is a peripherally acting mu-opioid receptor antagonist used to accelerate the recovery of gastrointestinal function following certain bowel surgeries, particularly partial bowel resection with primary anastomosis. It works by selectively blocking opioid receptors in the gastrointestinal tract, counteracting the effects of opioid pain medications on intestinal motility while generally preserving their central analgesic effects. Alvimopan is administered orally in a restricted hospital-based treatment programme, with use typically limited to a short perioperative course. Common adverse effects include nausea, vomiting, abdominal discomfort, and diarrhoea. It is contraindicated in patients who have taken therapeutic opioid doses for more than seven consecutive days immediately before treatment because of an increased risk of serious gastrointestinal adverse effects. Use requires appropriate patient selection and adherence to local prescribing restrictions.
Alvimopan was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Alvimopan, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Alvimopan from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Alvimopan, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
